<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:admin="http://webns.net/mvcb/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:content="http://purl.org/rss/1.0/modules/content/">

    <channel>
    
    <title>CBDepot.eu | Legal.Natural.Cannabinoids</title>
    <link>http://www.cbdepot.eu</link>
    <description>Legal.Natural.Cannabinoids</description>
    <dc:language>en</dc:language>
    <dc:creator>info@cbdepot.eu</dc:creator>
    <dc:rights>Copyright 2025</dc:rights>
    <dc:date>2025-10-21T08:52:00+00:00</dc:date>
    

    <item>
      <title><![CDATA[Dronabinol]]></title>
      <link>https://www.cbdepot.eu/products/dronabinol</link>
      <guid>https://www.cbdepot.eu/products/dronabinol#When:08:55:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/dronabinol"><img alt="Dronabinol" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/CB21_pharma_logo_turquoise_PANTONE-SMALL.jpg"/></a><br/><i>(–)-trans-delta-9-Tetrahydrocannabinol</i>]]></description>
      <dc:date>2025-10-21T08:55:00+00:00</dc:date>
    </item>

    <item>
      <title><![CDATA[Cannabidiol API]]></title>
      <link>https://www.cbdepot.eu/products/cannabidiol-api</link>
      <guid>https://www.cbdepot.eu/products/cannabidiol-api#When:08:53:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/cannabidiol-api"><img alt="Cannabidiol API" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/CB21_pharma_logo_turquoise_PANTONE-SMALL.jpg"/></a><br/><i>(–)-trans-Cannabidiol</i>
]]></description>
      <dc:date>2025-10-21T08:53:00+00:00</dc:date>
    </item>

    <item>
      <title><![CDATA[(–)-trans-Cannabidiol, pharma grade, isolated]]></title>
      <link>https://www.cbdepot.eu/products/cannabidiolum-gmp</link>
      <guid>https://www.cbdepot.eu/products/cannabidiolum-gmp#When:08:52:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/cannabidiolum-gmp"><img alt="(–)-trans-Cannabidiol, pharma grade, isolated" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/CB21_pharma_logo_turquoise_PANTONE-SMALL.jpg"/></a><br/>Active substance for pharmaceutical use.]]></description>
      <dc:date>2025-10-21T08:52:00+00:00</dc:date>
    </item>

    <item>
      <title><![CDATA[Refined Cannabis Extract]]></title>
      <link>https://www.cbdepot.eu/products/refined-cannabis-extract</link>
      <guid>https://www.cbdepot.eu/products/refined-cannabis-extract#When:08:51:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/refined-cannabis-extract"><img alt="Refined Cannabis Extract" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/CB21_pharma_logo_turquoise_PANTONE-SMALL.jpg"/></a><br/><i>Cannabis Extractum Raffinatum</i>]]></description>
      <dc:date>2025-10-21T08:51:00+00:00</dc:date>
    </item>

    <item>
      <title><![CDATA[Adjusted Cannabis Extract]]></title>
      <link>https://www.cbdepot.eu/products/adjusted-cannabis-extract</link>
      <guid>https://www.cbdepot.eu/products/adjusted-cannabis-extract#When:09:07:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/adjusted-cannabis-extract"><img alt="Adjusted Cannabis Extract" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/CB21_pharma_logo_turquoise_PANTONE-SMALL.jpg"/></a><br/><i>Cannabis Extractum Normatum</i>
]]></description>
      <dc:date>2025-10-20T09:07:00+00:00</dc:date>
    </item>

    <item>
      <title><![CDATA[(–)-trans-Cannabidiol, isolated]]></title>
      <link>https://www.cbdepot.eu/products/Cannabidiol-isolated</link>
      <guid>https://www.cbdepot.eu/products/Cannabidiol-isolated#When:13:12:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/Cannabidiol-isolated"><img alt="(–)-trans-Cannabidiol, isolated" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/Cannabidiol_CBD.jpg"/></a><br/>For professional use only, such as cosmetics, e-liquids and foods.
<br>
Novel Food authorization needed in EU for food use as per EU/2015/2283]]></description>
      <dc:date>2017-01-16T13:12:00+00:00</dc:date>
    </item>

    <item>
      <title><![CDATA[(–)-trans-Cannabidiol, synthesized]]></title>
      <link>https://www.cbdepot.eu/products/trans-cannabidiol-synthesized</link>
      <guid>https://www.cbdepot.eu/products/trans-cannabidiol-synthesized#When:13:11:00Z</guid>
      <description><![CDATA[<a href="https://www.cbdepot.eu/products/trans-cannabidiol-synthesized"><img alt="(–)-trans-Cannabidiol, synthesized" height="160" src="https://www.cbdepot.eu/images/cbdepot/_medium/Cannabidiol_CBD.jpg"/></a><br/>For professional use only, such as cosmetics, e-liquids and foods.
<br>
Novel Food authorization needed in EU for food use as per EU/2015/2283]]></description>
      <dc:date>2017-01-16T13:11:00+00:00</dc:date>
    </item>


    <item>
      <title><![CDATA[Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/repeated-treatment-with-cannabidiol-but-not-delta9-tetrahydrocannabinol-has</link>
      <guid>https://www.cbdepot.eu/cbd-research/repeated-treatment-with-cannabidiol-but-not-delta9-tetrahydrocannabinol-has#When:12:04:00Z</guid>
      <description><![CDATA[It is to be hoped that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.]]></description>
      <dc:date>2017-07-10T12:04:00+00:00</dc:date>
      <dc:subject><![CDATA[Stroke/TBI]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/protective-effects-of-cannabidiol-against-hippocampal-cell-death-and-cognit</link>
      <guid>https://www.cbdepot.eu/cbd-research/protective-effects-of-cannabidiol-against-hippocampal-cell-death-and-cognit#When:12:02:00Z</guid>
      <description><![CDATA[These findings suggest a protective effect of CBD on neuronal death induced by ischemia and indicate that CBD might exert beneficial therapeutic effects in brain ischemia.]]></description>
      <dc:date>2017-07-10T12:02:00+00:00</dc:date>
      <dc:subject><![CDATA[Stroke/TBI]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-administration-after-hypoxia-ischemia-to-newborn-rats-reduces-l</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-administration-after-hypoxia-ischemia-to-newborn-rats-reduces-l#When:11:59:00Z</guid>
      <description><![CDATA[n conclusion, CBD administration after HI injury to newborn rats led to long-lasting neuroprotection, with the overall effect of promoting greater functional rather than histological recovery.]]></description>
      <dc:date>2017-07-10T11:59:00+00:00</dc:date>
      <dc:subject><![CDATA[Stroke/TBI]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-prevents-infarction-via-the-non-cb1-cannabinoid-receptor-mechan</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-prevents-infarction-via-the-non-cb1-cannabinoid-receptor-mechan#When:11:57:00Z</guid>
      <description><![CDATA[These results surely show that the neuroprotective effect of Delta(9)-tetrahydrocannabinol are via a CB1 receptor and temperature-dependent mechanisms whereas the neuroprotective effects of cannabidiol are independent of CB1 blockade and of hypothermia.]]></description>
      <dc:date>2017-07-10T11:57:00+00:00</dc:date>
      <dc:subject><![CDATA[Stroke/TBI]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-nonpsychoactive-cannabis-constituent-protects-against-my</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-nonpsychoactive-cannabis-constituent-protects-against-my#When:11:41:00Z</guid>
      <description><![CDATA[Our study shows that CBD induces a substantial in vivo cardioprotective effect from ischemia that is not observed ex vivo.]]></description>
      <dc:date>2017-07-10T11:41:00+00:00</dc:date>
      <dc:subject><![CDATA[Stroke/TBI]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-anxiolytic-effect-of-cannabidiol-on-chronically-stressed-mice-depe</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-anxiolytic-effect-of-cannabidiol-on-chronically-stressed-mice-depe#When:10:33:00Z</guid>
      <description><![CDATA[hese findings support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated ]]></description>
      <dc:date>2017-07-06T10:33:00+00:00</dc:date>
      <dc:subject><![CDATA[Stress]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-treated-rats-exhibited-higher-motor-score-after-cryogenic-spina</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-treated-rats-exhibited-higher-motor-score-after-cryogenic-spina#When:09:46:00Z</guid>
      <description><![CDATA[Cannabidiol improved locomotor functional recovery and reduced injury extent, suggesting that it could be useful in the treatment of spinal cord lesions.]]></description>
      <dc:date>2017-06-23T09:46:00+00:00</dc:date>
      <dc:subject><![CDATA[Spinal cord injury]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-constituent-of-cannabis-sativa-modulates-sleep-in-rats</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-constituent-of-cannabis-sativa-modulates-sleep-in-rats#When:10:04:00Z</guid>
      <description><![CDATA[Since CBD induces alertness, it might be of therapeutic value in sleep disorders such as excessive somnolence.]]></description>
      <dc:date>2017-06-22T10:04:00+00:00</dc:date>
      <dc:subject><![CDATA[Sleep disorders]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-nonpsychoactive-cannabis-constituent-cannabidiol-is-a-wake-inducing-age</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-nonpsychoactive-cannabis-constituent-cannabidiol-is-a-wake-inducing-age#When:10:02:00Z</guid>
      <description><![CDATA[These findings suggest that this cannabinoid is a wake-inducing compound that presumably activates neurons in LH and DRN.]]></description>
      <dc:date>2017-06-22T10:02:00+00:00</dc:date>
      <dc:subject><![CDATA[Sleep disorders]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-exerts-sebostatic-and-antiinflammatory-effects-on-human-se1</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-exerts-sebostatic-and-antiinflammatory-effects-on-human-se1#When:10:07:00Z</guid>
      <description><![CDATA[Collectively, our findings suggest that, due to the combined lipostatic, antiproliferative, and antiinflammatory effects, CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris. ]]></description>
      <dc:date>2017-05-31T10:07:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-cannabis-sativa-constituent-as-an-antipsychotic-drug</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-cannabis-sativa-constituent-as-an-antipsychotic-drug#When:13:48:00Z</guid>
      <description><![CDATA[Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated.]]></description>
      <dc:date>2017-05-24T13:48:00+00:00</dc:date>
      <dc:subject><![CDATA[Schizophrenia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol as a potential treatment for psychosis. (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-as-a-potential-treatment-for-psychosis</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-as-a-potential-treatment-for-psychosis#When:13:38:00Z</guid>
      <description><![CDATA[Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment. ]]></description>
      <dc:date>2017-05-24T13:38:00+00:00</dc:date>
      <dc:subject><![CDATA[Schizophrenia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-enhances-anandamide-signaling-and-alleviates-psychotic-sym</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-enhances-anandamide-signaling-and-alleviates-psychotic-sym#When:13:36:00Z</guid>
      <description><![CDATA[The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.]]></description>
      <dc:date>2017-05-24T13:36:00+00:00</dc:date>
      <dc:subject><![CDATA[Schizophrenia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Medical use of cannabis. Cannabidiol: a new light for schizophrenia? (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/medical-use-of-cannabis.-cannabidiol-a-new-light-for-schizophrenia</link>
      <guid>https://www.cbdepot.eu/cbd-research/medical-use-of-cannabis.-cannabidiol-a-new-light-for-schizophrenia#When:13:27:00Z</guid>
      <description><![CDATA[Behavioural and neurochemical models suggest that CBD has a pharmacological profile similar to that of atypical anti-psychotic drugs and a clinical trial reported that this cannabinoid is a well-tolerated alternative treatment for schizophrenia.]]></description>
      <dc:date>2017-05-24T13:27:00+00:00</dc:date>
      <dc:subject><![CDATA[Schizophrenia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/a-critical-review-of-the-antipsychotic-effects-of-cannabidiol-30-years-of-a</link>
      <guid>https://www.cbdepot.eu/cbd-research/a-critical-review-of-the-antipsychotic-effects-of-cannabidiol-30-years-of-a#When:13:25:00Z</guid>
      <description><![CDATA[These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.]]></description>
      <dc:date>2017-05-24T13:25:00+00:00</dc:date>
      <dc:subject><![CDATA[Schizophrenia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/antipsychotic-like-effects-of-cannabidiol-and-rimonabant-systematic-review</link>
      <guid>https://www.cbdepot.eu/cbd-research/antipsychotic-like-effects-of-cannabidiol-and-rimonabant-systematic-review#When:13:21:00Z</guid>
      <description><![CDATA[The results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs.]]></description>
      <dc:date>2017-05-24T13:21:00+00:00</dc:date>
      <dc:subject><![CDATA[Schizophrenia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-as-an-emergent-therapeutic-strategy-for-lessening-the-impact-of</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-as-an-emergent-therapeutic-strategy-for-lessening-the-impact-of#When:10:48:00Z</guid>
      <description><![CDATA[In this context, the related nonpsychotropic cannabinoid cannabidiol, which may interact with the endocannabinoid system but has actions that are distinct, offers promise as a prototype for anti-inflammatory drug development.]]></description>
      <dc:date>2017-04-27T10:48:00+00:00</dc:date>
      <dc:subject><![CDATA[Rheumatism]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-anxiolytic-effect-of-cannabidiol-on-chronically-stressed-mice-depends-o</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-anxiolytic-effect-of-cannabidiol-on-chronically-stressed-mice-depends-o#When:12:58:00Z</guid>
      <description><![CDATA[These findings support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signalling.]]></description>
      <dc:date>2017-04-24T12:58:00+00:00</dc:date>
      <dc:subject><![CDATA[PTSD]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-blocks-long-lasting-behavioral-consequences-of-predator-threat</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-blocks-long-lasting-behavioral-consequences-of-predator-threat#When:12:53:00Z</guid>
      <description><![CDATA[Our results suggest that CBD has beneficial potential for PTSD treatment and that 5HT1A receptors could be a therapeutic target in this disorder.]]></description>
      <dc:date>2017-04-24T12:53:00+00:00</dc:date>
      <dc:subject><![CDATA[PTSD]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/nonpsychoactive-cannabidiol-prevents-prion-accumulation-and-protects-neuron</link>
      <guid>https://www.cbdepot.eu/cbd-research/nonpsychoactive-cannabidiol-prevents-prion-accumulation-and-protects-neuron#When:14:08:00Z</guid>
      <description><![CDATA[When combined with its ability to target the brain and its lack of toxic side effects, CBD may represent a promising new anti-prion drug.]]></description>
      <dc:date>2017-02-08T14:08:00+00:00</dc:date>
      <dc:subject><![CDATA[Prion/Mad Cow disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol for the treatment of psychosis in Parkinson&#8217;s disease (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-for-the-treatment-of-psychosis-in-parkinsons-disease</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-for-the-treatment-of-psychosis-in-parkinsons-disease#When:15:08:00Z</guid>
      <description><![CDATA[These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.]]></description>
      <dc:date>2017-02-06T15:08:00+00:00</dc:date>
      <dc:subject><![CDATA[Parkinson's disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/regulation-of-bone-mass-bone-loss-and-osteoclast-activity-by-cannabinoid-re</link>
      <guid>https://www.cbdepot.eu/cbd-research/regulation-of-bone-mass-bone-loss-and-osteoclast-activity-by-cannabinoid-re#When:12:48:00Z</guid>
      <description><![CDATA[These studies show that the CB1 receptor has a role in the regulation of bone mass and ovariectomy-induced bone loss and that CB1- and CB2-selective cannabinoid receptor antagonists are a new class of osteoclast inhibitors that may be of value in the treatment of osteoporosis and other bone diseases.]]></description>
      <dc:date>2017-01-31T12:48:00+00:00</dc:date>
      <dc:subject><![CDATA[Osteoporosis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Peripheral cannabinoid receptor, CB2, regulates bone mass. (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/peripheral-cannabinoid-receptor-cb2-regulates-bone-mass</link>
      <guid>https://www.cbdepot.eu/cbd-research/peripheral-cannabinoid-receptor-cb2-regulates-bone-mass#When:12:36:00Z</guid>
      <description><![CDATA[These results demonstrate that the endocannabinoid system is essential for the maintenance of normal bone mass by osteoblastic and osteoclastic CB2 signaling. Hence, CB2 offers a molecular target for the diagnosis and treatment of osteoporosis, the most prevalent degenerative disease in developed countries.]]></description>
      <dc:date>2017-01-31T12:36:00+00:00</dc:date>
      <dc:subject><![CDATA[Osteoporosis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoid-receptor-type-1-protects-against-age-related-osteoporosis-by-re</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoid-receptor-type-1-protects-against-age-related-osteoporosis-by-re#When:12:35:00Z</guid>
      <description><![CDATA[The CB1 receptor is therefore unique in that it regulates peak bone mass through an effect on osteoclast activity, but protects against age-related bone loss by regulating adipocyte and osteoblast differentiation of bone marrow stromal cells.]]></description>
      <dc:date>2017-01-31T12:35:00+00:00</dc:date>
      <dc:subject><![CDATA[Osteoporosis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoids and bone: friend or foe? (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoids-and-bone-friend-or-foe</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoids-and-bone-friend-or-foe#When:12:32:00Z</guid>
      <description><![CDATA[These data indicate that cannabinoid receptors and the enzymes responsible for ligand synthesis and breakdown play important roles in bone remodeling and in the pathogenesis of joint disease.]]></description>
      <dc:date>2017-01-31T12:32:00+00:00</dc:date>
      <dc:subject><![CDATA[Osteoporosis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-major-non-psychotropic-cannabis-constituent-enhances-fracture</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-major-non-psychotropic-cannabis-constituent-enhances-fracture#When:12:29:00Z</guid>
      <description><![CDATA[Taken together, these data show that CBD leads to improvement in fracture healing and demonstrate the critical mechanical role of collagen crosslinking enzymes. ]]></description>
      <dc:date>2017-01-31T12:29:00+00:00</dc:date>
      <dc:subject><![CDATA[Osteoporosis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol promotes browning in 3T3-L1 adipocytes (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-promotes-browning-in-3t3-l1-adipocytes</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-promotes-browning-in-3t3-l1-adipocytes#When:13:20:00Z</guid>
      <description><![CDATA[CBD may be explored as a potentially promising therapeutic agent for the prevention of obesity. ]]></description>
      <dc:date>2017-01-26T13:20:00+00:00</dc:date>
      <dc:subject><![CDATA[Obesity]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/role-of-the-cannabinoid-system-in-pain-control-and-therapeutic-implications</link>
      <guid>https://www.cbdepot.eu/cbd-research/role-of-the-cannabinoid-system-in-pain-control-and-therapeutic-implications#When:14:54:00Z</guid>
      <description><![CDATA[Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis.]]></description>
      <dc:date>2017-01-24T14:54:00+00:00</dc:date>
      <dc:subject><![CDATA[Neuropathic Pain]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/vanilloid-trpv1-receptor-mediates-the-antihyperalgesic-effect-of-the-nonpsy</link>
      <guid>https://www.cbdepot.eu/cbd-research/vanilloid-trpv1-receptor-mediates-the-antihyperalgesic-effect-of-the-nonpsy#When:14:50:00Z</guid>
      <description><![CDATA[These results demonstrate that TRPV1 receptor could be a molecular target of the CBD antihyperalgesic action.]]></description>
      <dc:date>2017-01-24T14:50:00+00:00</dc:date>
      <dc:subject><![CDATA[Neuropathic Pain]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-non-psychoactive-cannabis-constituent-cannabidiol-is-an-orally-effectiv</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-non-psychoactive-cannabis-constituent-cannabidiol-is-an-orally-effectiv#When:14:48:00Z</guid>
      <description><![CDATA[The results indicate a potential for therapeutic use of cannabidiol in chronic painful states.]]></description>
      <dc:date>2017-01-24T14:48:00+00:00</dc:date>
      <dc:subject><![CDATA[Neuropathic Pain]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-neuroinflammation-and-promotes-neuroplasticity-and-func</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-neuroinflammation-and-promotes-neuroplasticity-and-func#When:09:43:00Z</guid>
      <description><![CDATA[Collectively, the present results demonstrate that short-term CBD treatment results in global functional recovery in ischemic mice and impacts multiple and distinct targets involved in the pathophysiology of brain ischemic injury.]]></description>
      <dc:date>2017-01-18T09:43:00+00:00</dc:date>
      <dc:subject><![CDATA[Neurodegeneration]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/transdermal-delivery-of-cannabidiol-attenuates-binge-alcohol-induced-n</link>
      <guid>https://www.cbdepot.eu/cbd-research/transdermal-delivery-of-cannabidiol-attenuates-binge-alcohol-induced-n#When:09:40:00Z</guid>
      <description><![CDATA[These results demonstrate the feasibility of using CBD transdermal delivery systems for the treatment of alcohol-induced neurodegeneration.]]></description>
      <dc:date>2017-01-18T09:40:00+00:00</dc:date>
      <dc:subject><![CDATA[Neurodegeneration]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-for-neurodegenerative-disorders-important-new-clinical-applicat</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-for-neurodegenerative-disorders-important-new-clinical-applicat#When:09:38:00Z</guid>
      <description><![CDATA[CBD acts not only through the endocannabinoid system, but also causes direct or indirect activation of metabotropic receptors for serotonin or adenosine, and can target nuclear receptors of the PPAR family and also ion channels.]]></description>
      <dc:date>2017-01-18T09:38:00+00:00</dc:date>
      <dc:subject><![CDATA[Neurodegeneration]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Regulation of nausea and vomiting by cannabinoids (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/regulation-of-nausea-and-vomiting-by-cannabinoids</link>
      <guid>https://www.cbdepot.eu/cbd-research/regulation-of-nausea-and-vomiting-by-cannabinoids#When:12:13:00Z</guid>
      <description><![CDATA[Preclinical research indicates that cannabinioids, including CBD, may be effective clinically for treating both nausea and vomiting produced by chemotherapy or other therapeutic treatments.]]></description>
      <dc:date>2017-01-12T12:13:00+00:00</dc:date>
      <dc:subject><![CDATA[Nausea]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats (2017)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-non-psychoactive-component-of-cannabis-and-its-synthetic-dime</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-non-psychoactive-component-of-cannabis-and-its-synthetic-dime#When:12:12:00Z</guid>
      <description><![CDATA[These results suggest that cannabinoids without psychoactive side-effects may have therapeutic value in the treatment of chemotherapy-induced nausea.]]></description>
      <dc:date>2017-01-12T12:12:00+00:00</dc:date>
      <dc:subject><![CDATA[Nausea]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-provides-long-lasting-protection-against-the-deleterious-effect</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-provides-long-lasting-protection-against-the-deleterious-effect#When:09:59:00Z</guid>
      <description><![CDATA[Our findings highlight the anti-inflammatory effects of CBD in this viral model of MS and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component. ]]></description>
      <dc:date>2016-12-13T09:59:00+00:00</dc:date>
      <dc:subject><![CDATA[Multiple sclerosis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/dexamethasone-alleviates-motion-sickness-in-rats-in-part-by-enhancing-the-e</link>
      <guid>https://www.cbdepot.eu/cbd-research/dexamethasone-alleviates-motion-sickness-in-rats-in-part-by-enhancing-the-e#When:10:49:00Z</guid>
      <description><![CDATA[The results showed that dexamethasone lowered the motion sickness index and restored the levels of endogenous cannabinoids and the expression of the endocannabinoid CB1 receptor.]]></description>
      <dc:date>2016-10-27T10:49:00+00:00</dc:date>
      <dc:subject><![CDATA[Motion sickness]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Effects of cannabidiol (CBD) on regional cerebral blood flow (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/effects-of-cannabidiol-cbd-on-regional-cerebral-blood-flow1</link>
      <guid>https://www.cbdepot.eu/cbd-research/effects-of-cannabidiol-cbd-on-regional-cerebral-blood-flow1#When:10:55:00Z</guid>
      <description><![CDATA[These results suggest that CBD has anxiolytic properties, and that these effects are mediated by an action on limbic and paralimbic brain areas.]]></description>
      <dc:date>2016-10-24T10:55:00+00:00</dc:date>
      <dc:subject><![CDATA[Mood disorders]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The endocannabinoid system and migraine (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-endocannabinoid-system-and-migraine</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-endocannabinoid-system-and-migraine#When:09:59:00Z</guid>
      <description><![CDATA[The available results strongly suggest that activation of ECS could represent a promising therapeutical tool for reducing both the physiological and inflammatory components of pain that are likely involved in migraine attacks.]]></description>
      <dc:date>2016-10-18T09:59:00+00:00</dc:date>
      <dc:subject><![CDATA[Migraine]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoids and hallucinogens for headache (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoids-and-hallucinogens-for-headache</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoids-and-hallucinogens-for-headache#When:09:55:00Z</guid>
      <description><![CDATA[Cannabinoids in particular have a long history of use in the abortive and prophylactic treatment of migraine before prohibition and are still used by patients as a migraine abortive in particular. ]]></description>
      <dc:date>2016-10-18T09:55:00+00:00</dc:date>
      <dc:subject><![CDATA[Migraine]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoids-and-endocannabinoids-in-metabolic-disorders-with-focus-on-diab</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoids-and-endocannabinoids-in-metabolic-disorders-with-focus-on-diab#When:12:17:00Z</guid>
      <description><![CDATA[On the other hand, evidence is emerging that some nonpsychotropic plant cannabinoids, such as cannabidiol, can be employed to retard β-cell damage in type 1 diabetes.]]></description>
      <dc:date>2016-10-11T12:17:00+00:00</dc:date>
      <dc:subject><![CDATA[Metabolic syndrome]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The potential use of cannabidiol in the therapy of metabolic syndrome (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-potential-use-of-cannabidiol-in-the-therapy-of-metabolic-syndrome1</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-potential-use-of-cannabidiol-in-the-therapy-of-metabolic-syndrome1#When:12:15:00Z</guid>
      <description><![CDATA[Cannabidiol has an immunomodulating effect, as well, that helps lessen the progression of atherosclerosis induced by high glucose level.]]></description>
      <dc:date>2016-10-11T12:15:00+00:00</dc:date>
      <dc:subject><![CDATA[Metabolic syndrome]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/therapeutic-potential-of-cannabidiol-against-ischemia-reperfusion-liver-inj</link>
      <guid>https://www.cbdepot.eu/cbd-research/therapeutic-potential-of-cannabidiol-against-ischemia-reperfusion-liver-inj#When:14:23:00Z</guid>
      <description><![CDATA[These results emphasize that cannabidiol represents a potential therapeutic option to protect the liver against hypoxia-reoxygenation injury.]]></description>
      <dc:date>2016-09-21T14:23:00+00:00</dc:date>
      <dc:subject><![CDATA[Liver disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-causes-activated-hepatic-stellate-cell-death-through-a-mechanis</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-causes-activated-hepatic-stellate-cell-death-through-a-mechanis#When:14:21:00Z</guid>
      <description><![CDATA[We propose that CBD, by selectively inducing death of activated HSCs, represents a potential therapeutic agent for the treatment of liver fibrosis.]]></description>
      <dc:date>2016-09-21T14:21:00+00:00</dc:date>
      <dc:subject><![CDATA[Liver disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-protects-against-hepatic-ischemia-reperfusion-injury-by-attenua</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-protects-against-hepatic-ischemia-reperfusion-injury-by-attenua#When:14:18:00Z</guid>
      <description><![CDATA[CBD may represent a novel, protective strategy against I/R injury by attenuating key inflammatory pathways and oxidative/nitrative tissue injury, independent of classical CB1/2 receptors.]]></description>
      <dc:date>2016-09-21T14:18:00+00:00</dc:date>
      <dc:subject><![CDATA[Liver disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cisplatin-induced-nephrotoxicity-by-decreasing-</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cisplatin-induced-nephrotoxicity-by-decreasing-#When:11:07:00Z</guid>
      <description><![CDATA[Our results suggest that cannabidiol may represent a promising new protective strategy against cisplatin-induced nephrotoxicity.]]></description>
      <dc:date>2016-09-12T11:07:00+00:00</dc:date>
      <dc:subject><![CDATA[Kidney disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-intestinal-inflammation-through-the-control-of-neu1</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-intestinal-inflammation-through-the-control-of-neu1#When:10:07:00Z</guid>
      <description><![CDATA[Our results therefore indicate that CBD indeed unravels a new therapeutic strategy to treat inflammatory bowel diseases.]]></description>
      <dc:date>2016-09-07T10:07:00+00:00</dc:date>
      <dc:subject><![CDATA[Irritable bowel]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol in inflammatory bowel diseases: a brief overview (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-in-inflammatory-bowel-diseases-a-brief-overview</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-in-inflammatory-bowel-diseases-a-brief-overview#When:10:03:00Z</guid>
      <description><![CDATA[This strategic interaction makes CBD as a potential candidate for the development of a new class of anti-IBD drugs.]]></description>
      <dc:date>2016-09-07T10:03:00+00:00</dc:date>
      <dc:subject><![CDATA[Irritable bowel]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Even high doses of oral cannabidiol do not cause THC-like effects in humans (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/even-high-doses-of-oral-cannabidiol-do-not-cause-thc-like-effects-in-humans</link>
      <guid>https://www.cbdepot.eu/cbd-research/even-high-doses-of-oral-cannabidiol-do-not-cause-thc-like-effects-in-humans#When:09:12:00Z</guid>
      <description><![CDATA[Comment on „Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid” by John Merrick and colleagues (Merrick J, et al. Cannabis and Cannabinoid Research 2016;1(1):102-112.)]]></description>
      <dc:date>2016-09-02T09:12:00+00:00</dc:date>
      <dc:subject><![CDATA[]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cisplatin-induced-nephrotoxicity-by-decreasing-oxida</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cisplatin-induced-nephrotoxicity-by-decreasing-oxida#When:13:56:00Z</guid>
      <description><![CDATA[Our results suggest that cannabidiol may represent a promising new protective strategy against cisplatin-induced nephrotoxicity.]]></description>
      <dc:date>2016-07-21T13:56:00+00:00</dc:date>
      <dc:subject><![CDATA[Inflammation]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-high-glucose-induced-endothelial-cell-inflammatory-r</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-high-glucose-induced-endothelial-cell-inflammatory-r#When:13:53:00Z</guid>
      <description><![CDATA[Our results suggest that CBD may have significant therapeutic benefits against diabetic complications and atherosclerosis.]]></description>
      <dc:date>2016-07-21T13:53:00+00:00</dc:date>
      <dc:subject><![CDATA[Inflammation]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-intestinal-inflammation-through-the-control-of-neu</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-intestinal-inflammation-through-the-control-of-neu#When:13:49:00Z</guid>
      <description><![CDATA[Our results therefore indicate that CBD indeed unravels a new therapeutic strategy to treat inflammatory bowel diseases.]]></description>
      <dc:date>2016-07-21T13:49:00+00:00</dc:date>
      <dc:subject><![CDATA[Inflammation]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-non-psychotropic-plant-derived-cannabinoid-decreases-inflamma</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-non-psychotropic-plant-derived-cannabinoid-decreases-inflamma#When:13:24:00Z</guid>
      <description><![CDATA[We show that cannabidiol has anti-inflammatory effects in a murine model of acute lung injury.]]></description>
      <dc:date>2016-07-21T13:24:00+00:00</dc:date>
      <dc:subject><![CDATA[Inflammation]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Prospects for cannabinoid therapies in basal ganglia disorders (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/prospects-for-cannabinoid-therapies-in-basal-ganglia-disorders</link>
      <guid>https://www.cbdepot.eu/cbd-research/prospects-for-cannabinoid-therapies-in-basal-ganglia-disorders#When:11:16:00Z</guid>
      <description><![CDATA[The evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB(2) receptors may represent promising therapeutic agents in HD and PD, thus deserving a prompt clinical evaluation.]]></description>
      <dc:date>2016-07-19T11:16:00+00:00</dc:date>
      <dc:subject><![CDATA[Huntington's Disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Controlled clinical trial of cannabidiol in Huntington&#8217;s disease (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/controlled-clinical-trial-of-cannabidiol-in-huntingtons-disease</link>
      <guid>https://www.cbdepot.eu/cbd-research/controlled-clinical-trial-of-cannabidiol-in-huntingtons-disease#When:11:11:00Z</guid>
      <description><![CDATA[In summary, CBD, at an average daily dose of about 700 mg/day for 6 weeks, was neither symptomatically effective nor toxic, relative to placebo, in neuroleptic-free patients with HD.]]></description>
      <dc:date>2016-07-19T11:11:00+00:00</dc:date>
      <dc:subject><![CDATA[Huntington's Disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/a-novel-control-of-human-keratin-expression-cannabinoid-receptor-1-mediated</link>
      <guid>https://www.cbdepot.eu/cbd-research/a-novel-control-of-human-keratin-expression-cannabinoid-receptor-1-mediated#When:12:07:00Z</guid>
      <description><![CDATA[Taken together, our results suggest that cannabinoids and their receptors constitute a novel, clinically relevant control element of human K6 and K16 expression.]]></description>
      <dc:date>2016-04-19T12:07:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Epigenetic control of skin differentiation genes by phytocannabinoids (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/epigenetic-control-of-skin-differentiation-genes-by-phytocannabinoids</link>
      <guid>https://www.cbdepot.eu/cbd-research/epigenetic-control-of-skin-differentiation-genes-by-phytocannabinoids#When:12:03:00Z</guid>
      <description><![CDATA[These findings show that the phytocannabinoids cannabidiol and cannabigerol are transcriptional repressors that can control cell proliferation and differentiation.]]></description>
      <dc:date>2016-04-19T12:03:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-endocannabinoid-system-of-the-skin-in-health-and-disease-novel-perspect</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-endocannabinoid-system-of-the-skin-in-health-and-disease-novel-perspect#When:12:01:00Z</guid>
      <description><![CDATA[The disruption of this delicate balance might facilitate the development of multiple pathological conditions and diseases of the skin (e.g. acne, seborrhea, allergic dermatitis, itch and pain, psoriasis, hair growth disorders, systemic sclerosis and cancer).]]></description>
      <dc:date>2016-04-19T12:01:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-exerts-sebostatic-and-antiinflammatory-effects-on-human-se</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-exerts-sebostatic-and-antiinflammatory-effects-on-human-se#When:11:58:00Z</guid>
      <description><![CDATA[Collectively, our findings suggest that, due to the combined lipostatic, antiproliferative, and antiinflammatory effects, CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris. ]]></description>
      <dc:date>2016-04-19T11:58:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoids-inhibit-human-keratinocyte-proliferation-through-a-non-cb</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoids-inhibit-human-keratinocyte-proliferation-through-a-non-cb#When:11:41:00Z</guid>
      <description><![CDATA[Our results show that cannabinoids inhibit keratinocyte proliferation, and therefore support a potential role for cannabinoids in the treatment of psoriasis.]]></description>
      <dc:date>2016-04-19T11:41:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoids-inhibit-human-keratinocyte-proliferation-through-a-non-cb1-cb2</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoids-inhibit-human-keratinocyte-proliferation-through-a-non-cb1-cb2#When:11:41:00Z</guid>
      <description><![CDATA[Our results show that cannabinoids inhibit keratinocyte proliferation, and therefore support a potential role for cannabinoids in the treatment of psoriasis.]]></description>
      <dc:date>2016-04-19T11:41:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/topical-cannabinoid-agonists.-an-effective-new-possibility-for-treating-chr</link>
      <guid>https://www.cbdepot.eu/cbd-research/topical-cannabinoid-agonists.-an-effective-new-possibility-for-treating-chr#When:11:37:00Z</guid>
      <description><![CDATA[Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications.]]></description>
      <dc:date>2016-04-19T11:37:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Attenuation of allergic contact dermatitis through the endocannabinoid system. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/attenuation-of-allergic-contact-dermatitis-through-the-endocannabinoid-syst</link>
      <guid>https://www.cbdepot.eu/cbd-research/attenuation-of-allergic-contact-dermatitis-through-the-endocannabinoid-syst#When:11:31:00Z</guid>
      <description><![CDATA[These results demonstrate a protective role of the endocannabinoid system in contact allergy in the skin and suggest a target for therapeutic intervention.]]></description>
      <dc:date>2016-04-19T11:31:00+00:00</dc:date>
      <dc:subject><![CDATA[Skin conditions]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-protects-against-doxorubicin-induced-cardiomyopathy-by-modulati</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-protects-against-doxorubicin-induced-cardiomyopathy-by-modulati#When:11:09:00Z</guid>
      <description><![CDATA[These data suggest that CBD may represent a novel cardioprotective strategy against DOX-induced cardiotoxicity, and the above-described effects on mitochondrial function and biogenesis may contribute to its beneficial properties described in numerous other models of tissue injury. ]]></description>
      <dc:date>2016-04-19T11:09:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-a-nonpsychoactive-cannabis-constituent-protects-against-myocard</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-a-nonpsychoactive-cannabis-constituent-protects-against-myocard#When:11:05:00Z</guid>
      <description><![CDATA[In as much as CBD has previously been administered to humans without causing side effects, it may represent a promising novel treatment for myocardial ischemia.]]></description>
      <dc:date>2016-04-19T11:05:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-effect-of-cannabidiol-on-ischemia-reperfusion-induced-ventricular-arrhy</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-effect-of-cannabidiol-on-ischemia-reperfusion-induced-ventricular-arrhy#When:11:00:00Z</guid>
      <description><![CDATA[The present results demonstrated that CBD has an antiarrhythmic effect against I/R-induced arrhythmias, and the antiarrhythmic effect of CBD may be mediated through the activation of adenosine A1 receptor. ]]></description>
      <dc:date>2016-04-19T11:00:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cardiac-dysfunction-oxidative-stress-fibrosis-a</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cardiac-dysfunction-oxidative-stress-fibrosis-a#When:10:52:00Z</guid>
      <description><![CDATA[Collectively, these results coupled with the excellent safety and tolerability profile of CBD in humans, strongly suggest that it may have great therapeutic potential in the treatment of diabetic complications, and perhaps other cardiovascular disorders, by attenuating oxidative/nitrative stress, inflammation, cell death and fibrosis.]]></description>
      <dc:date>2016-04-19T10:52:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/acute-administration-of-cannabidiol-in-vivo-suppresses-ischaemia-induced-ca</link>
      <guid>https://www.cbdepot.eu/cbd-research/acute-administration-of-cannabidiol-in-vivo-suppresses-ischaemia-induced-ca#When:10:46:00Z</guid>
      <description><![CDATA[This study demonstrates that CBD is cardioprotective in the acute phase of I/R by both reducing ventricular arrhythmias and attenuating infarct size.]]></description>
      <dc:date>2016-04-19T10:46:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Is the cardiovascular system a therapeutic target for cannabidiol? (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/is-the-cardiovascular-system-a-therapeutic-target-for-cannabidiol</link>
      <guid>https://www.cbdepot.eu/cbd-research/is-the-cardiovascular-system-a-therapeutic-target-for-cannabidiol#When:10:30:00Z</guid>
      <description><![CDATA[Taken together, these preclinical data appear to support a positive role for CBD treatment in the heart, and in peripheral and cerebral vasculature.]]></description>
      <dc:date>2016-04-19T10:30:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol as an anti-arrhythmic, the role of the CB1 receptors (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-as-an-anti-arrhythmic-the-role-of-the-cb1-receptors</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-as-an-anti-arrhythmic-the-role-of-the-cb1-receptors#When:10:24:00Z</guid>
      <description><![CDATA[The observed synergism which persists when CB1 receptors are blocked prior to CBD administration, suggests cross-talk between CB1 and other CB receptors in the heart during ischaemia. ]]></description>
      <dc:date>2016-04-19T10:24:00+00:00</dc:date>
      <dc:subject><![CDATA[Heart disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/effect-of-sublingual-application-of-cannabinoids-on-intraocular-pressu</link>
      <guid>https://www.cbdepot.eu/cbd-research/effect-of-sublingual-application-of-cannabinoids-on-intraocular-pressu#When:08:22:00Z</guid>
      <description><![CDATA[A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40 mg CBD produced a transient increase IOP rise.]]></description>
      <dc:date>2016-04-07T08:22:00+00:00</dc:date>
      <dc:subject><![CDATA[Glaucoma]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/neuroprotective-effect-of-delta9-tetrahydrocannabinol-and-cannabidiol-in-n</link>
      <guid>https://www.cbdepot.eu/cbd-research/neuroprotective-effect-of-delta9-tetrahydrocannabinol-and-cannabidiol-in-n#When:08:20:00Z</guid>
      <description><![CDATA[These results suggest the potential use of CBD as a novel topical therapy for the treatment of glaucoma.]]></description>
      <dc:date>2016-04-07T08:20:00+00:00</dc:date>
      <dc:subject><![CDATA[Glaucoma]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabis-use-in-patients-with-fibromyalgia-effect-on-symptoms-relief-and-he</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabis-use-in-patients-with-fibromyalgia-effect-on-symptoms-relief-and-he#When:08:15:00Z</guid>
      <description><![CDATA[The use of cannabis was associated with beneficial effects on some FM symptoms. Further studies on the usefulness of cannabinoids in FM patients as well as cannabinoid system involvement in the pathophysiology of this condition are warranted.]]></description>
      <dc:date>2016-04-07T08:15:00+00:00</dc:date>
      <dc:subject><![CDATA[Fibromyalgia]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The cannabinoids as potential antiepileptics (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-cannabinoids-as-potential-antiepileptics</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-cannabinoids-as-potential-antiepileptics#When:13:40:00Z</guid>
      <description><![CDATA[The anticonvulsant nature of cannabidiol suggests that it has a therapeutic potential in at least three of the four major types of epilepsy: grand mal, cortical focal, and complex partial seizures.]]></description>
      <dc:date>2016-03-31T13:40:00+00:00</dc:date>
      <dc:subject><![CDATA[Epilepsy]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Hypnotic and antiepileptic effects of cannabidiol. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/hypnotic-and-antiepileptic-effects-of-cannabidiol</link>
      <guid>https://www.cbdepot.eu/cbd-research/hypnotic-and-antiepileptic-effects-of-cannabidiol#When:13:38:00Z</guid>
      <description><![CDATA[Seven out of the eight epileptics receiving cannabidiol had improvement of their disease state, whereas only one placebo patient improved.]]></description>
      <dc:date>2016-03-31T13:38:00+00:00</dc:date>
      <dc:subject><![CDATA[Epilepsy]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-displays-antiepileptiform-and-antiseizure-properties-in-vitro-a</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-displays-antiepileptiform-and-antiseizure-properties-in-vitro-a#When:13:30:00Z</guid>
      <description><![CDATA[We demonstrate the potential of CBD as a novel antiepileptic drug in the unmet clinical need associated with generalized seizures.]]></description>
      <dc:date>2016-03-31T13:30:00+00:00</dc:date>
      <dc:subject><![CDATA[Epilepsy]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-exerts-anti-convulsant-effects-in-animal-models-of-temporal-lob</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-exerts-anti-convulsant-effects-in-animal-models-of-temporal-lob#When:12:41:00Z</guid>
      <description><![CDATA[These results extend the anti-convulsant profile of CBD; when combined with a reported absence of psychoactive effects, this evidence strongly supports CBD as a therapeutic candidate for a diverse range of human epilepsies.]]></description>
      <dc:date>2016-03-31T12:41:00+00:00</dc:date>
      <dc:subject><![CDATA[Epilepsy]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Chronic administration of cannabidiol to healthy volunteers and epileptic patients (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/chronic-administration-of-cannabidiol-to-healthy-volunteers-and-epilep</link>
      <guid>https://www.cbdepot.eu/cbd-research/chronic-administration-of-cannabidiol-to-healthy-volunteers-and-epilep#When:12:19:00Z</guid>
      <description><![CDATA[The potential use of CBD as an antiepileptic drug and its possible potentiating effect on other antiepileptic drugs are discussed.]]></description>
      <dc:date>2016-03-31T12:19:00+00:00</dc:date>
      <dc:subject><![CDATA[Epilepsy]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabinoids-alter-endothelial-function-in-the-zucker-rat-model-of-type-2-d</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabinoids-alter-endothelial-function-in-the-zucker-rat-model-of-type-2-d#When:11:12:00Z</guid>
      <description><![CDATA[These studies suggest that increased circulating endocannabinoids may alter vascular function both positively and negatively in type 2 diabetes, and that part of the beneficial effect of cannabidiol in diabetes may be due to improved endothelium-dependent vasorelaxation.]]></description>
      <dc:date>2016-01-27T11:12:00+00:00</dc:date>
      <dc:subject><![CDATA[Diabetes]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol arrests onset of autoimmune diabetes in NOD mice. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-arrests-onset-of-autoimmune-diabetes-in-nod-mice</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-arrests-onset-of-autoimmune-diabetes-in-nod-mice#When:11:10:00Z</guid>
      <description><![CDATA[Our data strengthen our previous assumption that CBD, known to be safe in man, can possibly be used as a therapeutic agent for treatment of type 1 diabetes.]]></description>
      <dc:date>2016-01-27T11:10:00+00:00</dc:date>
      <dc:subject><![CDATA[Diabetes]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/neuroprotective-and-blood-retinal-barrier-preserving-effects-of-cannabidiol</link>
      <guid>https://www.cbdepot.eu/cbd-research/neuroprotective-and-blood-retinal-barrier-preserving-effects-of-cannabidiol#When:11:08:00Z</guid>
      <description><![CDATA[These results demonstrate that CBD treatment reduces neurotoxicity, inflammation, and BRB breakdown in diabetic animals through activities that may involve inhibition of p38 MAP kinase.]]></description>
      <dc:date>2016-01-27T11:08:00+00:00</dc:date>
      <dc:subject><![CDATA[Diabetes]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-lowers-incidence-of-diabetes-in-non-obese-diabetic-mice</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-lowers-incidence-of-diabetes-in-non-obese-diabetic-mice#When:10:57:00Z</guid>
      <description><![CDATA[Our results indicate that CBD can inhibit and delay destructive insulitis and inflammatory Th1-associated cytokine production in NOD mice resulting in a decreased incidence of diabetes possibly through an immunomodulatory mechanism shifting the immune response from Th1 to Th2 dominance.]]></description>
      <dc:date>2016-01-27T10:57:00+00:00</dc:date>
      <dc:subject><![CDATA[Diabetes]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cardiac-dysfunction-oxidative-stress-fibrosis-and-in</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-attenuates-cardiac-dysfunction-oxidative-stress-fibrosis-and-in#When:10:51:00Z</guid>
      <description><![CDATA[Collectively, these results coupled with the excellent safety and tolerability profile of CBD in humans, strongly suggest that it may have great therapeutic potential in the treatment of diabetic complications, and perhaps other cardiovascular disorders, by attenuating oxidative/nitrative stress, inflammation, cell death and fibrosis.]]></description>
      <dc:date>2016-01-27T10:51:00+00:00</dc:date>
      <dc:subject><![CDATA[Diabetes]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/expression-of-cannabinoid-receptors-in-human-osteoarthritic-cartilage-impli</link>
      <guid>https://www.cbdepot.eu/cbd-research/expression-of-cannabinoid-receptors-in-human-osteoarthritic-cartilage-impli#When:10:43:00Z</guid>
      <description><![CDATA[Cannabinoids designed to bind to receptors inhibiting the catabolic and pain pathways within the arthritic joint, while avoiding psychoactive effects, could provide potential arthritis therapies.]]></description>
      <dc:date>2016-01-27T10:43:00+00:00</dc:date>
      <dc:subject><![CDATA[Arthritis]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/antidepressant-like-effect-of-delta9-tetrahydrocannabinol-and-other-cannabi</link>
      <guid>https://www.cbdepot.eu/cbd-research/antidepressant-like-effect-of-delta9-tetrahydrocannabinol-and-other-cannabi#When:11:37:00Z</guid>
      <description><![CDATA[Results of this study show that Delta(9)-THC and other cannabinoids exert antidepressant-like actions, and thus may contribute to the overall mood-elevating properties of cannabis.]]></description>
      <dc:date>2016-01-20T11:37:00+00:00</dc:date>
      <dc:subject><![CDATA[Depression]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa (2016)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/antidepressant-like-and-anxiolytic-like-effects-of-cannabidiol-a-chemical-c</link>
      <guid>https://www.cbdepot.eu/cbd-research/antidepressant-like-and-anxiolytic-like-effects-of-cannabidiol-a-chemical-c#When:11:31:00Z</guid>
      <description><![CDATA[Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor. ]]></description>
      <dc:date>2016-01-20T11:31:00+00:00</dc:date>
      <dc:subject><![CDATA[Depression]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-intestinal-inflammation-through-the-control-of-neuroimm</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-reduces-intestinal-inflammation-through-the-control-of-neuroimm#When:15:34:00Z</guid>
      <description><![CDATA[Our results therefore indicate that CBD indeed unravels a new therapeutic strategy to treat inflammatory bowel diseases.]]></description>
      <dc:date>2015-12-30T15:34:00+00:00</dc:date>
      <dc:subject><![CDATA[Colitis Disease,Crohn's Disease]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Towards the use of non-psychoactive cannabinoids for prostate cancer. (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/towards-the-use-of-non-psychoactive-cannabinoids-for-prostate-cancer1</link>
      <guid>https://www.cbdepot.eu/cbd-research/towards-the-use-of-non-psychoactive-cannabinoids-for-prostate-cancer1#When:11:21:00Z</guid>
      <description><![CDATA[In the British Journal of Pharmacology, De Petrocellis and colleagues present comprehensive evidence that plant-derived cannabinoids, especially cannabidiol, are potent inhibitors of prostate carcinoma viability in vitro. ]]></description>
      <dc:date>2015-12-27T11:21:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/in-vitro-anticancer-activity-of-plant-derived-cannabidiol-on-prostate-</link>
      <guid>https://www.cbdepot.eu/cbd-research/in-vitro-anticancer-activity-of-plant-derived-cannabidiol-on-prostate-#When:11:15:00Z</guid>
      <description><![CDATA[Cannabidiol and other non-habit forming cannabinoids could be used as novel therapeutic agents for the treatment of prostate cancer.]]></description>
      <dc:date>2015-12-27T11:15:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-induced-apoptosis-in-human-leukemia-cells-a-novel-role-of-canna</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-induced-apoptosis-in-human-leukemia-cells-a-novel-role-of-canna#When:11:10:00Z</guid>
      <description><![CDATA[Exposure of leukemia cells to cannabidiol led to cannabinoid receptor 2 (CB2)-mediated reduction in cell viability and induction in apoptosis. ]]></description>
      <dc:date>2015-12-27T11:10:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium. (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-growth-and-induces-programmed-cell-death-in-kapos</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-growth-and-induces-programmed-cell-death-in-kapos#When:11:04:00Z</guid>
      <description><![CDATA[Cannabidiol (CBD), a plant-derived cannabinoid, exhibits promising antitumor effects without inducing psychoactive side effects.]]></description>
      <dc:date>2015-12-27T11:04:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/chemopreventive-effect-of-the-non-psychotropic-phytocannabinoid-cannabidiol</link>
      <guid>https://www.cbdepot.eu/cbd-research/chemopreventive-effect-of-the-non-psychotropic-phytocannabinoid-cannabidiol#When:16:28:00Z</guid>
      <description><![CDATA[It is concluded that cannabidiol exerts chemopreventive effect in vivo and reduces cell proliferation through multiple mechanisms.]]></description>
      <dc:date>2015-10-28T16:28:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/in-vitro-anticancer-activity-of-plant-derived-cannabidiol-on-prostate-cance</link>
      <guid>https://www.cbdepot.eu/cbd-research/in-vitro-anticancer-activity-of-plant-derived-cannabidiol-on-prostate-cance#When:16:16:00Z</guid>
      <description><![CDATA[Cannabidiol and other non-habit forming cannabinoids could be used as novel therapeutic agents for the treatment of prostate cancer.]]></description>
      <dc:date>2015-10-28T16:16:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Towards the use of non-psychoactive cannabinoids for prostate cancer (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/towards-the-use-of-non-psychoactive-cannabinoids-for-prostate-cancer</link>
      <guid>https://www.cbdepot.eu/cbd-research/towards-the-use-of-non-psychoactive-cannabinoids-for-prostate-cancer#When:16:12:00Z</guid>
      <description><![CDATA[De Petrocellis and colleagues present comprehensive evidence that plant-derived cannabinoids, especially cannabidiol, are potent inhibitors of prostate carcinoma viability in vitro.]]></description>
      <dc:date>2015-10-28T16:12:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/decrease-of-plasminogen-activator-inhibitor-1-may-contribute-to-the-anti-in</link>
      <guid>https://www.cbdepot.eu/cbd-research/decrease-of-plasminogen-activator-inhibitor-1-may-contribute-to-the-anti-in#When:11:31:00Z</guid>
      <description><![CDATA[Our data provide evidence for a hitherto unknown mechanism underlying the anti-invasive action of cannabidiol on human lung cancer cells.]]></description>
      <dc:date>2015-10-23T11:31:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cox-2-and-ppar-confer-cannabidiol-induced-apoptosis-of-human-lung-cancer-ce</link>
      <guid>https://www.cbdepot.eu/cbd-research/cox-2-and-ppar-confer-cannabidiol-induced-apoptosis-of-human-lung-cancer-ce#When:11:22:00Z</guid>
      <description><![CDATA[Together, our data show a novel proapoptotic mechanism of cannabidiol involving initial upregulation of COX-2 and PPAR-γ and a subsequent nuclear translocation of PPAR-γ by COX-2-dependent PGs.]]></description>
      <dc:date>2015-10-23T11:22:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1 (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-lung-cancer-cell-invasion-and-metastasis-via-intercell</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-lung-cancer-cell-invasion-and-metastasis-via-intercell#When:11:18:00Z</guid>
      <description><![CDATA[Overall, our data indicate that cannabinoids induce ICAM-1, thereby conferring TIMP-1 induction and subsequent decreased cancer cell invasiveness.]]></description>
      <dc:date>2015-10-23T11:18:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-cancer-cell-invasion-via-upregulation-of-tissue-inhibi</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-cancer-cell-invasion-via-upregulation-of-tissue-inhibi#When:14:40:00Z</guid>
      <description><![CDATA[Altogether, these findings provide a novel mechanism underlying the anti-invasive action of cannabidiol and imply its use as a therapeutic option for the treatment of highly invasive cancers.]]></description>
      <dc:date>2015-10-22T14:40:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[Cannabidiol inhibits angiogenesis by multiple mechanisms (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-angiogenesis-by-multiple-mechanisms</link>
      <guid>https://www.cbdepot.eu/cbd-research/cannabidiol-inhibits-angiogenesis-by-multiple-mechanisms#When:14:11:00Z</guid>
      <description><![CDATA[This study reveals that CBD inhibits angiogenesis by multiple mechanisms. Its dual effect on both tumour and endothelial cells supports the hypothesis that CBD has potential as an effective agent in cancer therapy.]]></description>
      <dc:date>2015-10-22T14:11:00+00:00</dc:date>
      <dc:subject><![CDATA[Cancer]]></dc:subject>
    </item>

    <item>
      <title><![CDATA[The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke (2015)]]></title>
      <link>https://www.cbdepot.eu/cbd-research/the-role-of-cannabinoids-in-inflammatory-modulation-of-allergic-respiratory</link>
      <guid>https://www.cbdepot.eu/cbd-research/the-role-of-cannabinoids-in-inflammatory-modulation-of-allergic-respiratory#When:08:19:00Z</guid>
      <description><![CDATA[The presence of endocannabinoid machinery in the central nervous system, together with high levels of CB1 expression, suggests that the endocannabinoid system is an important modulator of neuroinflammation and a possible drug target.]]></description>
      <dc:date>2015-09-25T08:19:00+00:00</dc:date>
      <dc:subject><![CDATA[Asthma]]></dc:subject>
    </item>
  
    </channel>
</rss>